MVA-based SARS-CoV-2 Vaccine MVA-SARS-2-S

**Semantic type:** Immunologic Factor|Pharmacologic Substance

**Definition:** A vaccine comprised of a recombinant modified Vaccinia virus Ankara (MVA) viral vector expressing full-length severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) surface antigen spike (S) protein, with potential immunizing activity against SARS-CoV-2. Upon administration of the MVA-based SARS-CoV-2 Vaccine MVA-SARS-2-S, the SARS-CoV-2 S protein is presented to the immune system. This may activate both humoral and cellular immune responses which may result in protection against SARS-CoV-2 infection.

**Synonyms:** - MVA-SARS-2-S - MVA-based Covid-19 Vaccine MVA-SARS-2-S